Dividends: A Modest Proposal

by

The pursuit of income, dear reader, is a comedy. A tragedy, for some. But mostly a comedy. Investors, bless their optimistic hearts, are forever squabbling over the perfect dividend stock. Is it the yield? The growth rate? One might as well debate the ideal length of a mustache – a matter of personal preference, and often, a touch of absurdity.

The numbers, however, whisper a secret. Over the past half-century, those companies in the S&P 500 who generously increased their payouts have enjoyed a rather respectable 10.2% annual return. Those who merely sat on their coffers, hoarding capital like misers, managed a paltry 6.8%. It seems even Wall Street understands the virtue of sharing, at least a little. And those who were a bit more generous with their cash tended to do better than the stingy ones. A lesson for us all, perhaps.

Today, we turn our gaze toward the healthcare sector, a veritable fountain of both profit and, shall we say, peculiar ailments. We’ve identified two specimens worthy of closer inspection – companies that offer a blend of yield and growth, a combination as rare and delightful as a truthful politician.

Johnson & Johnson

Johnson & Johnson, a name synonymous with bandages and, increasingly, complex pharmaceuticals, currently boasts a dividend yield of 2.2%. Nearly double the S&P 500 average. A respectable showing, though one suspects a significant portion of their profits are derived from soothing our collective hypochondria. They’ve been steadily increasing their dividend for 63 consecutive years, earning them the title of “Dividend King.” A regal designation, though one wonders if they employ a royal accountant to keep track of it all.

Their financial health is, shall we say, robust. A pristine AAA bond rating – a distinction shared by so few, it’s practically an exclusive club. Last year, they generated $20 billion in free cash flow, enough to cover their $12.4 billion in dividends with a comfortable margin. One imagines their treasury department sleeps soundly at night.

Loading widget...

And they don’t simply hoard their wealth. Johnson & Johnson invested $14.7 billion in research and development last year, chasing the next blockbuster drug. They also acquired Intra-Cellular Therapies for $14.6 billion and Halda Therapeutics for $3.1 billion, bolstering their neuroscience and cancer treatment divisions. A clear signal that they intend to remain at the forefront of medical innovation – and, naturally, profit from it.

Medtronic

Medtronic, a purveyor of medical technology, offers a dividend yield of 2.8%. They’ve increased their dividend annually for 48 years, a testament to their enduring success. One suspects their shareholders are a remarkably healthy – and wealthy – bunch.

Loading widget...

Their financial footing is equally solid. They generated $5.2 billion in free cash flow last year, easily covering their $3.6 billion in dividend payments. Their A-rated balance sheet suggests they’re not about to succumb to any financial maladies. And they invest a considerable $2.7 billion in R&D, searching for the next technological breakthrough. They recently acquired Cathworks for $585 million, adding another piece to their ever-expanding portfolio. A shrewd move, one might say, in a market where growth is the ultimate elixir.

A Modest Proposal for Your Portfolio

Johnson & Johnson and Medtronic, dear reader, represent a compelling combination of yield and growth. They pay out a respectable dividend while consistently reinvesting in their future. A sensible strategy, wouldn’t you agree? Adding them to your income portfolio is not merely a financial decision; it’s an acknowledgement that even in the chaotic world of high finance, a little stability – and a steady stream of income – can go a long way. Perhaps, just perhaps, it’s a recipe for a slightly less absurd existence.

Read More

2026-02-08 20:12